Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 11/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 7/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970423 | 0.89 | MAPK1 (0.56) | RBP4DPP4DPP8DPP9DPP7 | |
| SCHEMBL5644483 | 0.87 | DPP4 (0.50) | RBP4DPP4DPP8DPP9DPP7 | |
| SCHEMBL1424003 | 0.83 | DPP4 (0.46) | RBP4DPP4DPP8DPP9DPP7 | |
| SCHEMBL19124072 | 0.82 | DPP4 (0.54) | RBP4DPP4DPP8DPP9DPP7 | |
| SCHEMBL24157629 | 0.81 | MAPK1 (0.53) | RBP4MAPK1EP300CREBBPBRD4 | |
| SCHEMBL17232648 | 0.79 | EP300 (0.49) | RBP4MAPK1EP300CREBBPBRD4 | |
| SCHEMBL19831854 | 0.78 | MAPK1 (0.45) | RBP4MAPK1EP300CREBBPBRD4 | |
| SCHEMBL18880484 | 0.78 | MAPK1 (0.47) | RBP4MAPK1EP300CREBBPBRD4 | |
| SCHEMBL1423800 | 0.77 | CYP2C19 (0.49) | RBP4DPP4DPP8DPP9DPP7 | |
| SCHEMBL23881432 | 0.76 | DPP4 (0.40) | RBP4DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| WO-2013074388-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | GPR119, GPR27, GCGR | RBP4 1259/4885DPP4 620/4885DPP8 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.